Amytrx Therapeuticsincis A Clinical Stage Biopharmaceutical Company Located In Nashvilletnfounded In April 2014The Company Is Focused On Developing Innovative Peptide Therapies Aimed At Treating Inflammatory Diseasesits Lead Compoundamtx 100Is A First In Class Peptide Therapeutic Currently In A Phase 2B Clinical Trial For Mild To Moderate Atopic Dermatitisthe Company Is Also Exploring Treatments For Other Inflammatory Skin Conditionsincluding Psoriasisrosaceaand Acne The Leadership Team Includes President And Ceo Matthew Agondaalong With Key Members Such As Chief Business Officer Randall Briggs And Svp Of Research & Development Vernon Lalvarezamytrx Employs Patented Cell Penetrating Peptides And Conducts Extensive Testing In Animal Models To Validate Its Therapeutic Concepts Before Moving To Human Trialsthe Company Is Committed To Advancing The Health And Lives Of Patients Suffering From Chronic Inflammatory Conditions
